[HTML][HTML] Therapeutic strategies for COVID-19: progress and lessons learned
G Li, R Hilgenfeld, R Whitley, E De Clercq - Nature Reviews Drug …, 2023 - nature.com
Abstract The coronavirus disease 2019 (COVID-19) pandemic has stimulated tremendous
efforts to develop therapeutic strategies that target severe acute respiratory syndrome …
efforts to develop therapeutic strategies that target severe acute respiratory syndrome …
SARS-CoV-2 spike S2-specific neutralizing antibodies
CJ Li, SC Chang - Emerging Microbes & Infections, 2023 - Taylor & Francis
Since the onset of the coronavirus disease 2019 (COVID-19), numerous neutralizing
antibodies (NAbs) against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) …
antibodies (NAbs) against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) …
[HTML][HTML] Broadly neutralizing anti-S2 antibodies protect against all three human betacoronaviruses that cause deadly disease
Pan-betacoronavirus neutralizing antibodies may hold the key to developing broadly
protective vaccines against novel pandemic coronaviruses and to more effectively respond …
protective vaccines against novel pandemic coronaviruses and to more effectively respond …
[HTML][HTML] Prefusion-stabilized SARS-CoV-2 S2-only antigen provides protection against SARS-CoV-2 challenge
Abstract Ever-evolving SARS-CoV-2 variants of concern (VOCs) have diminished the
effectiveness of therapeutic antibodies and vaccines. Developing a coronavirus vaccine that …
effectiveness of therapeutic antibodies and vaccines. Developing a coronavirus vaccine that …
[HTML][HTML] SARS-CoV-2 omicron variants harbor spike protein mutations responsible for their attenuated fusogenic phenotype
Since the emergence of the Omicron variants at the end of 2021, they quickly became the
dominant variants globally. The Omicron variants may be more easily transmitted compared …
dominant variants globally. The Omicron variants may be more easily transmitted compared …
An engineered recombinant protein containing three structural domains in SARS-CoV-2 S2 protein has potential to act as a pan-human coronavirus entry inhibitor or …
X Wang, L Sun, Z Liu, L Xing, Y Zhu, W Xu… - Emerging Microbes & …, 2023 - Taylor & Francis
The threat to global health caused by three highly pathogenic human coronaviruses (HCoV),
SARS-CoV-2, MERS-CoV and SARS-CoV, calls for the development of pan-HCoV …
SARS-CoV-2, MERS-CoV and SARS-CoV, calls for the development of pan-HCoV …
[HTML][HTML] A recent SARS-CoV-2 infection enhances antibody-dependent cellular cytotoxicity against Several Omicron subvariants following a fourth mRNA vaccine …
G Beaudoin-Bussières, A Tauzin, K Dionne… - Viruses, 2023 - mdpi.com
Since the beginning of the SARS-CoV-2 pandemic, several variants of concern (VOCs),
such as the Alpha, Beta, Gamma, Delta and Omicron variants, have arisen and spread …
such as the Alpha, Beta, Gamma, Delta and Omicron variants, have arisen and spread …
[HTML][HTML] Functional and antigenic characterization of SARS-CoV-2 spike fusion peptide by deep mutational scanning
The fusion peptide of SARS-CoV-2 spike protein is functionally important for membrane
fusion during virus entry and is part of a broadly neutralizing epitope. However, sequence …
fusion during virus entry and is part of a broadly neutralizing epitope. However, sequence …
[HTML][HTML] Engineered immunogens to elicit antibodies against conserved coronavirus epitopes
Immune responses to SARS-CoV-2 primarily target the receptor binding domain of the spike
protein, which continually mutates to escape acquired immunity. Other regions in the spike …
protein, which continually mutates to escape acquired immunity. Other regions in the spike …
Evidence of antigenic drift in the fusion machinery core of SARS-CoV-2 spike
Antigenic drift of SARS-CoV-2 is typically defined by mutations in the N-terminal domain and
receptor binding domain of spike protein. In contrast, whether antigenic drift occurs in the S2 …
receptor binding domain of spike protein. In contrast, whether antigenic drift occurs in the S2 …